NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 109.6 USD | +4.17% |
|
+1.57% | +9.56% |
| 07-15 | Brace for a flurry of speeches from Fed officials |  |
| 07-15 | European companies cut jobs as economy sputters | RE |
| Sales 2024 * | 49.29B 3,782B | Sales 2025 * | 51.41B 3,945B | Capitalization | 225B 17,292B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.99B 844B | Net income 2025 * | 12.22B 938B | EV / Sales 2024 * | 4.84 x |
| Net Debt 2024 * | 13.22B 1,015B | Net Debt 2025 * | 11.6B 890B | EV / Sales 2025 * | 4.61 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
18.5
x | Employees | 76,057 |
| Yield 2024 * |
3.36% | Yield 2025 * |
3.48% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More press releases
More news
| 1 day | +4.17% | ||
| 1 week | +1.57% | ||
| Current month | +5.34% | ||
| 1 month | +8.16% | ||
| 3 months | +17.00% | ||
| 6 months | +2.20% | ||
| Current year | +9.56% |
1 week
105.15
109.56
1 month
102.43109.56
Current year
90.24109.56
1 year
90.24109.56
3 years
72.98109.56
5 years
68.65109.56
10 years
66.35109.56
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 31/12/04 | |
| Director of Finance/CFO | 59 | 31/12/02 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 15/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 31/12/12 |
Simon Moroney
BRD | Director/Board Member | 65 | 27/02/20 |
| Chairman | 68 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/24 | 109.6 | +4.17% | 30,744 |
| 11/07/24 | 105.2 | -2.03% | 35,900 |
| 10/07/24 | 107.4 | -0.47% | 96,235 |
Delayed Quote OTC Markets, July 16, 2024 at 07:31 pm
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
18/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
110.4
USD
Average target price
112.7
USD
Spread / Average Target
+2.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 848B | |
| +33.05% | 627B | |
| -3.66% | 363B | |
| +15.06% | 318B | |
| +9.18% | 299B | |
| +13.58% | 243B | |
| +15.67% | 179B | |
| +2.47% | 167B | |
| +1.48% | 125B |
- Stock Market
- Equities
- NOVN Stock
- NVSEF Stock
